跳转至内容
Merck

V-022

Supelco

Vigabatrin solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C6H11NO2
分子量:
129.16
EC號碼:
分類程式碼代碼:
41116107
NACRES:
NA.24

等級

certified reference material

形狀

liquid

特點

Snap-N-Spike®/Snap-N-Shoot®

包裝

ampule of 1 mL

製造商/商標名

Cerilliant®

濃度

1.0 mg/mL in methanol

技術

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

應用

clinical testing

格式

single component solution

儲存溫度

−20°C

SMILES 字串

NC(CCC(O)=O)C=C

InChI

1S/C6H11NO2/c1-2-5(7)3-4-6(8)9/h2,5H,1,3-4,7H2,(H,8,9)

InChI 密鑰

PJDFLNIOAUIZSL-UHFFFAOYSA-N

基因資訊

human ... ABAT(18)

一般說明

Vigabatrin is a newer antiepileptic sold as Sabril® in the US, Canada, Mexico and the United Kingdom and as Sabrilex in Denmark. The drug is used as an adjunctive treatment of complex partial seizures in adults and for infantile spasms in pediatric patients one month to two years of age. This certified Snap-N-Spike® Solution standard is suitable for use in LC/MS or GC/MS applications including forensic analysis, clinical toxicology, urine drug testing, or pharmaceutical research.

法律資訊

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Sabril is a registered trademark of Lundbeck LLC
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

訊號詞

Danger

危險分類

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

標靶器官

Eyes

儲存類別代碼

3 - Flammable liquids

水污染物質分類(WGK)

WGK 1

閃點(°F)

49.5 °F - closed cup

閃點(°C)

9.7 °C - closed cup


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

The potential value of a negative finding: an illustrative example.
Kenneth Silverman et al.
JAMA psychiatry, 70(6), 571-572 (2013-04-12)
Peter Weber et al.
Epilepsy & behavior : E&B, 24(1), 138-140 (2012-04-17)
We report the case of an adolescent girl who suffered from symptomatic refractory focal epilepsy after an arteria cerebri media insult 15 years prior to this report. Five weeks after initiation of an add-on therapy with vigabatrin, she was seizure
O Heinzlef et al.
Revue neurologique, 168 Suppl 3, S62-S68 (2012-06-29)
The medicinal treatment of spasticity includes use of oral treatments (baclofène and tizanidine), botulinum toxin, intrathecal baclofène and local application of alcohol or phenol. However, spasticity may not be uncomfortable and may even be useful. Therefore, all spastic diseases do
Lisa M Clayton et al.
Ophthalmology, 119(10), 2152-2160 (2012-08-03)
To explore the relationship of peripapillary retinal nerve fiber layer (ppRNFL) thinning in individuals exposed to the antiepileptic drug vigabatrin with respect to 2 separate variables: cumulative vigabatrin exposure and severity of vigabatrin-associated visual field loss (VAVFL). Cross-sectional observational study.
C Y Go et al.
Neurology, 78(24), 1974-1980 (2012-06-13)
To update the 2004 American Academy of Neurology/Child Neurology Society practice parameter on treatment of infantile spasms in children. MEDLINE and EMBASE were searched from 2002 to 2011 and searches of reference lists of retrieved articles were performed. Sixty-eight articles

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门